Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most ...

Immutep Ltd.’s stock surged 31% on Tuesday morning following the news that it out-licensed rights to Dr. Reddy’s Laboratories Ltd. to develop and commercialize eftilagimod (IMP-321, efti) in selected ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

Impressive results of a potential second-line combination treatment for multiple myeloma from the Majestec-3 trial of teclistamab plus daratumumab raised eyebrows at the American Society of Hematology ...

Researchers at the Institut Pasteur have developed a vaccine that spurred the production of autoantibodies to immunoglobulin E (IgE) antibodies, protecting vaccinated mice from anaphylaxis. In their ...

Crescent Biopharma Inc. teamed with Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. to generate “parallel” data of its ...

Epiminder Ltd. raised AU$125 million (US$82.99 million) in its initial public offering on the Australian Securities Exchange ...

With new results from Wave Life Sciences Ltd., Structure Therapeutics Inc. and Ascletis Pharma Inc., obesity management drugs ...

Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and ...

The U.S. FDA’s clearance of Medtronic plc’s Hugo robotic-assisted surgery (RAS) system is certainly a boon for the company ...

Jesse Tettero presented data supporting the use of a measurable residual disease (MRD) surrogate endpoint in acute myeloid leukemia (AML) research. Through the Harmony Alliance study of 1,858 pooled ...

Mirum Pharmaceuticals Inc. is buying privately held Bluejay Therapeutics Inc., an $820 million purchase that will bring it Bluejay’s lead asset, brelovitug, for treating chronic hepatitis D virus.